Search
for

    Sort by

    Research

    780-786 / 786 results
      Table 1

      research Table 1

      December 2021
      Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.
      Table 2

      research Table 2

      December 2021
      Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.

      research Male-Pattern Hair Loss: Comprehensive Identification of the Associated Genes as a Basis for Understanding Pathophysiology

      April 2023 in “Medizinische Genetik”
      Male-pattern hair loss (MPHL) is a common condition affecting up to 80% of European men, with significant genetic underpinnings. Genome-wide association studies (GWAS) have identified 389 risk loci and key genes such as AR, SRD5A2, WNT10A, and IRF4, which are involved in hair growth and pigmentation. These findings explain approximately 39% of the phenotypic variance in MPHL and suggest a heritability of 60-70%. The document highlights the need for larger cohorts and comprehensive genetic analyses to fully understand MPHL's genetic and non-genetic factors, aiming to develop precision medicine approaches and improved treatments.
    ← Previous page